Milestone Scient Stock Price, News & Analysis

Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs and develops computerized injection technologies and instruments for medical, dental and cosmetic applications. The company is described in its public disclosures as a developer of computerized drug delivery instruments that provide painless and precise injections, with systems designed to make injections precise, efficient and to increase overall patient comfort and safety.

According to Milestone Scientific, its computer-controlled systems are built around its proprietary DPS Dynamic Pressure Sensing Technology®. These instruments are designed to regulate flow rate and monitor pressure from the tip of the needle, supporting the development of next-generation devices for subcutaneous drug delivery, including local anesthetic. This technology underpins the company’s platforms in both the dental and medical markets.

Business focus and segments

Milestone Scientific states that it operates across dental and medical applications. In dentistry, the company develops, manufactures, markets and sells computer-controlled systems for the delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent, and the company also highlights the STA® Single Tooth Anesthesia System and The Wand® STA System as core dental offerings. These systems are intended to support improved, and in the company’s words painless and precise, delivery of anesthetic during dental procedures.

On the medical side, Milestone Scientific points to its CompuFlo® technology and the CompuFlo® Epidural System. The company describes CompuFlo as a platform that precisely identifies the epidural space with real-time pressure feedback, and as a technology used in interventional pain management and spinal procedures. Milestone Scientific notes that CompuFlo has been supported by clinical leaders and that its epidural system has been assigned a Medicare Part B payment rate under CPT® code 0777T in several jurisdictions, with early activity from commercial insurers.

Dental market activities

In its news releases, Milestone Scientific reports ongoing initiatives within its dental segment, including expanding direct sales programs in North America, securing new international registrations for the STA Single Tooth Anesthesia System, and enhancing omnichannel digital marketing to increase brand awareness and recurring e-commerce sales. The company has also launched The Wand® Ambassador Program, a peer-to-peer engagement initiative in which experienced dental professionals share clinical insights, workflow considerations and firsthand experiences with The Wand STA System to support education and adoption in the dental market.

The company states that the Ambassador Program is intended to expand clinical awareness and adoption of The Wand STA System by connecting interested practices with Milestone’s commercial and clinical support teams for product demonstrations, training and evaluation of clinical and operational benefits. Internal tools are described as providing visibility into engagement activity, which the company uses to measure and optimize program execution.

Medical market and pain management focus

Within the medical segment, Milestone Scientific highlights growing utilization and recurring revenue from CompuFlo disposables, as well as increasing interest from hospitals and international distributors. The company reports that it is advancing reimbursement strategies for CompuFlo, including securing Medicare payment-rate assignments and expanding commercial coverage, which it views as important for broader adoption in hospitals and pain-management settings.

Milestone Scientific also emphasizes the role of CompuFlo in interventional pain management and spine intervention markets. The company notes that its CompuFlo Epidural System provides real-time pressure feedback to identify the epidural space and has been positioned as an alternative to traditional loss-of-resistance techniques. It reports that clinical leaders have validated the technology and that payer-related developments, such as Medicare Part B payment rates and initial commercial insurer interest, support integration into routine clinical practice.

Corporate initiatives and operations

Milestone Scientific’s public communications describe ongoing transformation and growth initiatives under its leadership team. These include actions to strengthen its dental and medical businesses, reduce operating expenses, and build a leaner, more focused organization. The company reports efforts to strengthen its sales infrastructure, improve organizational alignment, and prioritize initiatives with what it describes as high near-term return potential.

The company’s disclosures also reference investments in specialized market analysis and reimbursement strategies for CompuFlo, and a guided relaunch of CompuFlo in the medical segment. In dental, Milestone Scientific notes that it is capitalizing on direct sales models, e-commerce platforms and targeted marketing campaigns to drive adoption of its STA system. The company further notes that it is pursuing international expansion through new registrations and distribution partners.

Exchange listing and regulatory context

Milestone Scientific Inc. is listed on the NYSE American under the ticker symbol MLSS. In an 8-K filing and related press release, the company reported receiving a letter from NYSE American stating that it was not in compliance with certain continued listing standards related to stockholders’ equity and historical losses. The company has indicated that it intends to submit a plan of compliance and that, while this process is underway, its common stock continues to trade on NYSE American under the MLSS symbol, subject to periodic review by the exchange.

In its proxy and 8-K filings, Milestone Scientific outlines typical corporate governance matters, including annual meetings of stockholders, election of directors, amendments to its Restated Certificate of Incorporation to increase authorized shares of common stock, and ratification of its independent auditors. These filings provide additional detail on voting procedures, record dates, and other governance processes.

Technology platform

Across its public statements, Milestone Scientific consistently highlights its proprietary DPS Dynamic Pressure Sensing Technology® as the foundation of its injection systems. The company describes this platform as regulating flow rate and monitoring pressure from the tip of the needle, which it uses as a basis for developing devices for subcutaneous drug delivery and local anesthetic administration. This technology is presented as central to both its dental systems, such as STA and The Wand, and its medical systems, including CompuFlo.

Company positioning

Milestone Scientific characterizes itself as a technology-focused company operating at the intersection of medical research, device development and clinical practice in dentistry, medicine and cosmetic applications. Its disclosures emphasize a focus on computer-controlled injection systems, patient comfort and safety, and the use of pressure-sensing technology to guide procedures. The company reports that it is working to expand adoption of its technologies across dental practices, hospitals, pain-management settings and international markets, while also managing operating expenses and pursuing compliance with exchange listing requirements.